Skip to main content
Premium Trial:

Request an Annual Quote

Seahorse Bioscience Raises $5M in Private Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Seahorse Bioscience yesterday said that it has raised $5 million in a Series D private financing.

The North Billerica, Mass.-based maker of cell analysis instruments said that it would use proceeds form the offering to expand its domestic and international sales and marketing efforts for its XF series analyzers for measuring cell metabolism.

Seahorse CEO Jay Teich called the financing "a milestone" for the firm. "We will use the funds to double our worldwide sales coverage and will be hiring at our manufacturing plant in Chicopee, [Mass.], ensuring that we keep pace with market demand for our XF system," he said in a statement.

Investors in this round included Commonwealth Capital Ventures, FLIR Systems Inc, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures and HLM Venture Partners.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.